Compare · head to head
Ascentage Pharma Group vs CSL
CSL ranks higher overall — 360 rank 40 vs 26.
CSL leads on Value (65 vs 38) and Quality (64 vs 29). Ascentage Pharma Group leads on Growth (50 vs 26), Safety (50 vs 44) and Sentiment (57 vs 39).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | China | Australia |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Medium | X-Large |
| ISIN | KYG0519B1023 | AU000000CSL8 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 26 | 40 |
| Value | 38 | 65 |
| Quality | 29 | 64 |
| Growth | 50 | 26 |
| Safety | 50 | 44 |
| Sentiment | 57 | 39 |
| Quality details | ||
| Profitability | 24 | 59 |
| Cash Truth | 34 | 68 |
Ascentage Pharma Group vs Kyowa Hakko KirinAscentage Pharma Group vs Medical Developments InternationalAscentage Pharma Group vs MesoblastAscentage Pharma Group vs Telix PharmaceuticalsAdd a third stock →
Full analyses: Ascentage Pharma Group · CSL
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100